Anavex Life Sciences (AVXL) Return on Assets (2017 - 2025)
Anavex Life Sciences (AVXL) posted Return on Assets of 3.58% for Q4 2025, up 7.51% sequentially from 3.87% in Q3 2025, and down 357.0% YoY from 1.39% in Q4 2024.
Anavex Life Sciences (AVXL) Return on Assets (2017 - 2025) Analysis & Trends
Anavex Life Sciences has reported Return on Assets for 9 years, with the latest figure at 3.58% in Q4 2025.
- Quarterly Return on Assets fell 357.0% year-over-year to 3.58% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3.58% (down 357.0% YoY) and the FY2025 annual result came in at 3.32%, down 332.0% from the prior year.
- Return on Assets advanced to 3.58% in Q4 2025 per AVXL's latest filing, from 3.87% in the prior quarter.
- Over five years, Return on Assets peaked at 0.0% in Q3 2021 and troughed at 3.87% in Q3 2025.
- A 5-year average of 0.38% and a median of 0.0% in 2024 frame the typical range for Return on Assets.
- The sharpest annual moves came in 2021 and 2025: Return on Assets rose 1 bps in 2021, then sank 387 bps in 2025.
- Over 5 years, Return on Assets stood at 0.0% in 2021, then decreased by 30 bps to 0.0% in 2022, then increased by 14 bps to 0.0% in 2023, then sank by 216 bps to 0.01% in 2024, then plunged by 39554 bps to 3.58% in 2025.
- According to Business Quant data, Return on Assets over the past three periods registered 3.58%, 3.87%, and 0.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.01% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -3.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.58% |
| Sep 30, 2025 | -3.87% |
| Jun 30, 2025 | -0.02% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | 0.00% |